US Cystic Fibrosis Therapeutics Market Forecast and Company Analysis Report 2025-2033 Featuring Vertex, Abbvie, Novartis, Gilead Sciences, Viatris, Pfizer, AstraZeneca, and F. Hoffmann-La Roche

About this update from Vertex Pharmaceuticals Incorporated

The United States Cystic Fibrosis Therapeutics Market is set to grow from an estimated US$ 2.32 billion in 2024 to US$ 4.72 billion by 2033, with an 8.22% CAGR from 2025 to 2033. This growth is driven by advancements in gene therapy, increased access to CFTR modulators, and robust research initiatives. Key players like Vertex Pharmaceuticals and Abbvie leverage developments like Trikafta, expanding the therapeutic market. Challenges including high treatment costs and limited rural access persist, while states like California and New York lead in market demand and innovation. Advocacy organizations and healthcare infrastructure sustain this dynamic market environment. U.S. Cystic Fibrosis Therapeutics Market Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The "United States Cystic Fibrosis Therapeutics Market to See Strong Growth Through 2033 - Driven by Gene Therapy and CFTR Innovation" report has been added to ResearchAndMarkets.com's offering. The United States Cystic Fibrosis Therapeutics Market is expected to reach US$ 2.32 billion in 2024 and further reach US$ 4.72 billion by the end of 2033 at a compound annual growth rate of 8.22% during the forecast period of 2025-2033. The growth is triggered by innovation in gene therapy, expanded patient access to CFTR modulators, enhanced awareness, and robust research efforts. In the United States, therapeutic growth for cystic fibrosis has been strong due to huge investment in research and development, well-established healthcare infrastructure, and early embracement of new therapies. The United States has a large population of diagnosed patients and organizations such as the Cystic Fibrosis Foundation, which aggressively encourage awareness, clinical trials, and patient support initiatives. As there are ongoing developments and greater exposure to precision medicine, popularity and performance of cystic fibrosis drugs continue to expand nationwide. Growth Drivers of the United States Cystic Fibrosis Therapeutics Market CFTR Modulator Therapies Advances Approval and development of CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulators have revolutionized the treatment of cystic fibrosis. These medications, like Trikafta (elexacaftor/tezacaftor/ivacaftor), attack the faulty protein that causes the disease at its root. They have dramatically enhanced life expectancy and quality of life. More FDA approvals, investments by major pharmaceutical companies, and continuous clinical trials for wider patient use are driving growth. As an increasing number of patients benefit from these high-impact treatments, the market continues to grow. December 2024, The FDA approved Vertex Pharmaceuticals' Alyftrek for cystic fibrosis patients aged 6 and older with at least one F508del mutation or another treatment-responsive CFTR gene mutation. This approval expands treatment options and offers a more convenient dosing regimen. Strong Support from Advocacy Organizations Nonprofit organizations such as the Cystic Fibrosis Foundation are key drivers of awareness, research funding, and drug development acceleration. These organizations provide patient access to clinical trials and enable government and private sector partnerships. Their actions not only enhanced patient outcomes but also brought new entrants and investors into the market. This ecosystem fosters innovation, accelerates regulatory processes, and maintains long-term U.S. market growth. High Prevalence and Early Diagnosis One of the highest prevalence rates of cystic fibrosis is found in the United States, with newborn screening programs available in all 50 states, guaranteeing early diagnosis. Early diagnosis supports early therapeutic intervention, enhancing outcome and driving demand for effective therapies. Improved genetic testing, public health infrastructure, and increasing awareness have driven the increase in diagnosed cases, extending the therapeutic market. This wide patient base still sustains a strong demand for new and current treatments. There are roughly 40,000 individuals with cystic fibrosis in the United States and roughly 100,000 globally. Roughly 1 in 30 individuals in the United States is a carrier. Challenges in United States Cystic Fibrosis Therapeutics Market High Cost of Treatment Cystic fibrosis treatments, especially CFTR modulators, are very costly - typically more than $300,000 per patient per year. This creates a tremendous economic burden for health systems, payers, and patients, reducing access. Even with insurance coverage and support programs, cost continues to be a deterrent for most. The pricing pressure also attracts regulatory attention and criticism, with the potential to impact market growth and innovation. Limited Access in Rural Areas While urban centers often have specialized CF care facilities, rural areas in the U.S. may lack access to expert care and advanced therapies. Transportation barriers, specialist shortages, and limited health education contribute to care disparities. Patients in these regions often experience delayed diagnosis or suboptimal treatment. Bridging this gap requires investment in telemedicine, outreach programs, and rural healthcare infrastructure - challenges that remain persistent. Cystic Fibrosis Therapeutics Products Launches in USA Key Players Analysis (Overviews, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis) Top 10 States Key Attributes: Key Topics Covered: 1. Introduction 2. Research & Methodology 2.1 Data Source 2.2 Research Approach 2.3 Forecast Projection Methodology 3. Executive Summary 4. Market Dynamics 4.1 Growth Drivers 4.2 Challenges 5. United States Cystic Fibrosis Therapeutics Market 5.1 Historical Market Trends 5.2 Market Forecast 6. Market Share Analysis 6.1 By Drugs Type 6.2 By Route of Administration 6.3 By Distribution Channel 6.4 By States 7. Drug Class 7.1 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) 7.2 Bronchodilators 7.3 Mucolytic 7.4 Pancreatic Enzyme Supplement 7.5 Others 8. Route of Administration 8.1 Oral Drugs 8.2 Inhaled Drugs 9. Distribution Channel 9.1 Hospitals 9.2 Retail Pharmacies 9.3 Others 10. Top 10 States 10.1 California 10.2 Texas 10.3 New York 10.4 Florida 10.5 Illinois 10.6 Pennsylvania 10.7 Ohio 10.8 Georgia 10.9 Washington 10.10 New Jersey 10.11 Rest of United States 11. Value Chain Analysis 12. Porter's Five Forces Analysis 12.1 Bargaining Power of Buyers 12.2 Bargaining Power of Suppliers 12.3 Degree of Competition 12.4 Threat of New Entrants 12.5 Threat of Substitutes 13. SWOT Analysis 13.1 Strength 13.2 Weakness 13.3 Opportunity 13.4 Threats 14. Cystic Fibrosis Drugs Insights 14.1 Marketed Drugs 14.1.1 TRIKAFTA: Vertex Pharmaceuticals 14.1.1.1 Product Description 14.1.1.2 Clinical Trial & Development 14.1.1.3 Safety and Efficacy 14.1.2 SYMDEKO: Vertex Pharmaceuticals 14.1.3 ORKAMBI: Vertex Pharmaceuticals 14.1.4 KALYDECO: Vertex Pharmaceuticals 14.2 Emerging Drugs 14.2.1 Ensifentrine: Verona Pharmaceuticals 14.2.2 ELX-02: Eloxx Pharmaceuticals 14.2.3 VX-121/TEZ/VX-561: Vertex Pharmaceuticals 14.2.4 POL6014 (Lonodelestat): Santhera Pharmaceuticals 14.2.5 LAU-7b: Laurent Pharmaceuticals 15. Pricing Benchmark Analysis 15.1 Vertex Pharmaceuticals 15.2 Abbvie Inc. 15.3 Novartis AG 15.4 Gilead Sciences 15.5 Viatris Inc 15.6 Pfizer 15.7 AstraZeneca 15.8 F. Hoffmann-La Roche Ltd 16. Key Players Analysis For more information about this report visit https://www.researchandmarkets.com/r/8twzdj About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

View stock analysis, news, and events for Vertex Pharmaceuticals Incorporated